The Cape Town Clinical Trials Unit (CT-CTU) is applying to become a DAIDS Unit for HIV/AIDS Clinical Trials. The administrative unit for the CT-CTU is based in the Desmond Tutu HIV Centre (DTHC) at the University of Cape Town (UCT) under the leadership of Professor Robin Wood, one of South Africa's leading experts in HIV care and treatment. The CT-CTU also includes expertise from the Infectious Diseases Epidemiology Unit and the Departments of Virology and Psychiatry at UCT. The CT-CTU is comprised of three Clinical Research Sites (CRSs) located within 10 miles of the DTHC, each applying within a single DAIDS Network priority area. The Nyanga CRS is led by Dr. Linda-Gail Bekker and is focused on Vaccine Research and Development with special emphasis on adolescents. The Gugulethu CRS specializes in Phase II and III clinical trials of Microbicides and other HIV Prevention interventions and is led by Dr. David Coetzee. The DTHC CRS, led by Professor Wood, has a long history of successful trials of antiretroviral therapy and is focused on the optimization of clinical management including co-morbidities. Each of these sites has a strong track-record in multisite HIV clinical trials, including a staff complement already in place to initiate research activities within 6 months of the grant award and maintains active Community Advisory Boards, which drive community involvement in clinical research. These Clinical Research Sites will be supported by a centralized Administrative & Scientific Core providing technical support in administration and finance, laboratory systems, data management, and training and regulatory requirements. This core, based at the DTHC, will maximize efficiency in the set-up and conduct of clinical trials at each CRS. The operations of the CT-CTU are greatly simplified by the location of all administrative and management structures within the University of Cape Town. In addition, this application features a Mentoring Partnership application linking the Nyanga CRS with the HVTN CRS of the Perinatal HIV Research Unit in Johannesburg, South Africa. This partnership will strengthen the capacity of the Nyanga CRS to conduct Phase I, II and III HIV vaccine trials through training and technical support, building on the already strong relationships between these two centres developed through collaboration in the NIH-funded CIPRA-SA grant. ? ? ADMINISTRATIVE COMPONENT: ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01AI069519-01
Application #
7097864
Study Section
Special Emphasis Panel (ZAI1-BLG-A (M1))
Program Officer
Pouliot, Eileen M
Project Start
2007-04-01
Project End
2014-01-31
Budget Start
2007-04-01
Budget End
2008-01-31
Support Year
1
Fiscal Year
2007
Total Cost
$979,642
Indirect Cost
Name
University of Cape Town
Department
Type
DUNS #
568227214
City
Rondebosch
State
Country
South Africa
Zip Code
7700
Leitman, Ellen M; Hurst, Jacob; Mori, Masahiko et al. (2016) Lower Viral Loads and Slower CD4+ T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02. J Infect Dis 214:379-89
Gray, Glenda E; Mayer, Kenneth H; Elizaga, Marnie L et al. (2016) Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. Clin Vaccine Immunol 23:496-506
Middelkoop, Keren; Mathema, Barun; Myer, Landon et al. (2015) Transmission of tuberculosis in a South African community with a high prevalence of HIV infection. J Infect Dis 211:53-61
Richardson, Eugene T; Morrow, Carl D; Kalil, Darryl B et al. (2014) Shared air: a renewed focus on ventilation for the prevention of tuberculosis transmission. PLoS One 9:e96334
Boren, David; Sullivan, Patrick S; Beyrer, Chris et al. (2014) Stochastic variation in network epidemic models: implications for the design of community level HIV prevention trials. Stat Med 33:3894-904
Hopkins, Kathryn L; Laher, Fatima; Otwombe, Kennedy et al. (2014) Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses. PLoS One 9:e103446
Middelkoop, Keren; Bekker, Linda-Gail; Mathema, Barun et al. (2014) Factors affecting tuberculosis strain success over 10 years in a high TB- and HIV-burdened community. Int J Epidemiol 43:1114-22
Bassett, Ingrid V; Govindasamy, Darshini; Erlwanger, Alison S et al. (2014) Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness. PLoS One 9:e85197
Kaplan, Richard; Caldwell, Judy; Middelkoop, Keren et al. (2014) Impact of ART on TB case fatality stratified by CD4 count for HIV-positive TB patients in Cape Town, South Africa (2009-2011). J Acquir Immune Defic Syndr 66:487-94
Wood, Robin; Morrow, Carl; Ginsberg, Samuel et al. (2014) Quantification of shared air: a social and environmental determinant of airborne disease transmission. PLoS One 9:e106622

Showing the most recent 10 out of 22 publications